Opinion|Videos|April 18, 2025
Benefits of Nonsteroidal Topical JAK Inhibitors for Moderate Pediatric Atopic Dermatitis
Author(s)James Song, MD, FAAD
James Song, MD, FAAD, discusses how topical Janus kinase inhibitors offer distinct advantages for children with moderate atopic dermatitis by providing effective inflammation control without the adverse effects of topical corticosteroids, particularly in sensitive areas like the face and intertriginous regions.
Advertisement
This news content has been independently developed and is not endorsed by the American Academy of Dermatology.
Video content above is prompted by the following:
- For children with moderate disease who may not yet require systemic therapy (or who aren’t eligible), what advantages would a nonsteroidal, topical Janus kinase inhibitor offer over current options?
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Global Hidradenitis Suppurativa Atlas (GHiSA) Finds HS Affects 1% of the World's Population
2
Delgocitinib Offers Targeted Relief for the Painful Burden of Chronic Hand Eczema
3
When Hives Do Not Quit: A Practical Update on Chronic Spontaneous Urticaria
4
Top 5 Articles of the Week: December 7-12
5
